ASTRAZENECA PLC — 6-K Filings
1,550 6-K filings on record
This page lists all 6-K filings submitted to the SEC by ASTRAZENECA PLC (AZN), sorted by most recent first. Each row links to the full filing on EdgarLookup. ASTRAZENECA PLC has filed 1,550 6-K documents with the SEC since 2018. To view all SEC filings by ASTRAZENECA PLC, see the full filings list.
All
11-K
144
20-F
20-F/A
25
25-NSE
3
3/A
4
424B2
424B3
424B5
425
6-K
6-K/A
8-A12B
8-A12B/A
CERT
CERTNYS
CORRESP
CT ORDER
DFAN14A
EFFECT
F-3
F-3ASR
F-4
F-4/A
F-6
F-6 POS
F-6EF
FWP
IRANNOTICE
NO ACT
S-1
S-8
S-8 POS
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SC TO-C
SC TO-T
SC TO-T/A
SCHEDULE 13D/A
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 6-K | NOTICE OF AGM | 0001654954-24-002749 | Mar 7, 2024 | — |
| 6-K | FORM 6-K | 0001104659-24-031683 | Mar 7, 2024 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-24-002688 | Mar 6, 2024 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-24-002690 | Mar 6, 2024 | — |
| 6-K | EMA VALIDATES DATO-DXD MAAS FOR NSQ NSCLC AND BC | 0001654954-24-002518 | Mar 4, 2024 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-24-002477 | Mar 1, 2024 | — |
| 6-K | FORM 6-K | 0001104659-24-027496 | Feb 26, 2024 | — |
| 6-K | VOYDEYA RECOMMENDED FOR EU APPROVAL | 0001654954-24-002155 | Feb 26, 2024 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-24-002028 | Feb 22, 2024 | — |
| 6-K | FORM 6-K | 0001104659-24-026359 | Feb 22, 2024 | — |
| 6-K | ASTRAZENECA PRICES A $5BN BOND OFFERING | 0001654954-24-002042 | Feb 22, 2024 | — |
| 6-K | FILING OF FORM 20-F WITH SEC | 0001654954-24-001982 | Feb 21, 2024 | — |
| 6-K | FORM 6-K | 0001104659-24-025224 | Feb 20, 2024 | — |
| 6-K | TAGRISSO PLUS CHEMO APPROVED IN US FOR LUNG CANCER | 0001654954-24-001908 | Feb 20, 2024 | — |
| 6-K | ANNUAL FINANCIAL REPORT | 0001654954-24-001937 | Feb 20, 2024 | — |
| 6-K | TAGRISSO IMPROVED PFS IN STAGE III LUNG CANCER | 0001654954-24-001899 | Feb 20, 2024 | Feb 19, 2024 |
| 6-K | FDA ACCEPTS DATO-DXD BLA FOR NONSQUAMOUS NSCLC | 0001654954-24-001903 | Feb 20, 2024 | — |
| 6-K | FORM 6-K | 0001104659-24-025540 | Feb 20, 2024 | — |
| 6-K | ASTRAZENECA COMPLETES ACQUISITION OF ICOSAVAX | 0001654954-24-001914 | Feb 20, 2024 | — |
| 6-K | FINAL RESULTS | 0001654954-24-001467 | Feb 8, 2024 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-24-001173 | Feb 1, 2024 | — |
| 6-K | FORM 6-K | 0001104659-24-005026 | Jan 19, 2024 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-24-000032 | Jan 2, 2024 | — |
| 6-K | ASTRAZENECA ACQUIRES GRACELL | 0001654954-23-015982 | Dec 27, 2023 | — |
| 6-K | FORM 6-K | 0001104659-23-129281 | Dec 26, 2023 | — |
| 6-K | WAINUA (EPLONTERSEN) GRANTED FIRST US FDA APPROVAL | 0001654954-23-015901 | Dec 22, 2023 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-23-015521 | Dec 14, 2023 | — |
| 6-K | ASTRAZENECA TO ACQUIRE ICOSAVAX | 0001654954-23-015390 | Dec 12, 2023 | — |
| 6-K | FORM 6-K | 0001104659-23-125420 | Dec 12, 2023 | — |
| 6-K | BLOCK LISTING INTERIM REVIEW | 0001654954-23-015044 | Dec 1, 2023 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-23-015043 | Dec 1, 2023 | — |
| 6-K | DISCONTINUATION OF TWO CRYSTALIZE EVIDENCE TRIALS | 0001654954-23-015010 | Dec 1, 2023 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-23-014734 | Nov 24, 2023 | — |
| 6-K | TRUQAP APPROVED IN US FOR HR+ BREAST CANCER | 0001654954-23-014510 | Nov 17, 2023 | — |
| 6-K | UPDATE ON PACIFIC-2 PHASE III TRIAL FOR IMFINZI | 0001654954-23-014199 | Nov 14, 2023 | — |
| 6-K | DIRECTOR DECLARATION | 0001654954-23-013975 | Nov 9, 2023 | — |
| 6-K | AGREEMENT WITH ECCOGENE FOR CLINICAL STAGE GLP-1RA | 0001654954-23-013971 | Nov 9, 2023 | — |
| 6-K | IMFINZI COMBINATION IMPROVES PFS IN LIVER CANCER | 0001654954-23-013973 | Nov 9, 2023 | — |
| 6-K | 9M AND Q3 2023 RESULTS | 0001654954-23-013969 | Nov 9, 2023 | Nov 2, 2023 |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-23-013666 | Nov 1, 2023 | — |
| 6-K | ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS | 0001654954-23-013630 | Nov 1, 2023 | — |
| 6-K | ASTRAZENECA SETTLES NEXIUM LIABILITY LITIGATIONS | 0001654954-23-012523 | Oct 3, 2023 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-23-012469 | Oct 2, 2023 | — |
| 6-K | DATO-DXD IMPROVED PFS IN BREAST CANCER | 0001654954-23-012206 | Sep 25, 2023 | Sep 22, 2023 |
| 6-K | ALEXION COMPLETES PFIZER GENE THERAPY AGREEMENT | 0001654954-23-012050 | Sep 20, 2023 | — |
| 6-K | ENHERTU RECOMMENDED IN EU FOR HER2-MUTANT NSCLC | 0001654954-23-011919 | Sep 15, 2023 | — |
| 6-K | FASENRA PHASE III EGPA TRIAL MET PRIMARY ENDPOINT | 0001654954-23-011717 | Sep 11, 2023 | — |
| 6-K | UPDATE ON US REVIEW OF ULTOMIRIS FOR NMOSD | 0001654954-23-011565 | Sep 6, 2023 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-23-011460 | Sep 1, 2023 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-23-009946 | Aug 1, 2023 | — |